Crohn’s Disease Patients See Promising Results in Stelara (Ustekinumab) Phase 3 Clinical Studies, Janssen Reports

Crohn’s Disease Patients See Promising Results in Stelara (Ustekinumab) Phase 3 Clinical Studies, Janssen Reports
Janssen Research & Development drug candidate Stelara (ustekinumab) demonstrated positive results in the IM-UNITI maintenance study investigating clinical remission effects in patients with moderate to severe Crohn's disease. The results showed that a significantly greater proportion of patients receiving Stelara subcutaneous (SC) maintenance therapy were in clinical remission after one year when compared to those on placebo. The positive clinical data was presented at the Digestive Disease Week 2016 May 21-24 in San Diego, California. Stelara is a monoclonal antibody antagonist of human interleukin-12 and interleukin-23, molecules that are believed to play a role in the autoimm
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *